vs

Side-by-side financial comparison of CABOT CORP (CBT) and Enovis CORP (ENOV). Click either name above to swap in a different company.

CABOT CORP is the larger business by last-quarter revenue ($849.0M vs $589.2M, roughly 1.4× Enovis CORP). CABOT CORP runs the higher net margin — 8.6% vs -1.4%, a 10.0% gap on every dollar of revenue. On growth, Enovis CORP posted the faster year-over-year revenue change (5.4% vs -11.1%). Over the past eight quarters, Enovis CORP's revenue compounded faster (5.9% CAGR vs -8.7%).

Cabot Corporation is an American specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company operates in over 20 countries with 36 manufacturing plants, eight research and development facilities, and 28 sales offices.

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.

CBT vs ENOV — Head-to-Head

Bigger by revenue
CBT
CBT
1.4× larger
CBT
$849.0M
$589.2M
ENOV
Growing faster (revenue YoY)
ENOV
ENOV
+16.5% gap
ENOV
5.4%
-11.1%
CBT
Higher net margin
CBT
CBT
10.0% more per $
CBT
8.6%
-1.4%
ENOV
Faster 2-yr revenue CAGR
ENOV
ENOV
Annualised
ENOV
5.9%
-8.7%
CBT

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CBT
CBT
ENOV
ENOV
Revenue
$849.0M
$589.2M
Net Profit
$73.0M
$-8.4M
Gross Margin
24.9%
62.0%
Operating Margin
15.2%
Net Margin
8.6%
-1.4%
Revenue YoY
-11.1%
5.4%
Net Profit YoY
-21.5%
EPS (diluted)
$1.37
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBT
CBT
ENOV
ENOV
Q1 26
$589.2M
Q4 25
$849.0M
$548.9M
Q3 25
$899.0M
$564.5M
Q2 25
$923.0M
$558.8M
Q1 25
$936.0M
Q4 24
$955.0M
$561.0M
Q3 24
$1.0B
$505.2M
Q2 24
$1.0B
$525.2M
Net Profit
CBT
CBT
ENOV
ENOV
Q1 26
$-8.4M
Q4 25
$73.0M
$-571.1M
Q3 25
$43.0M
$-36.7M
Q2 25
$101.0M
$-56.0M
Q1 25
$94.0M
Q4 24
$93.0M
$-703.2M
Q3 24
$137.0M
$-31.5M
Q2 24
$109.0M
$-18.6M
Gross Margin
CBT
CBT
ENOV
ENOV
Q1 26
62.0%
Q4 25
24.9%
59.9%
Q3 25
24.5%
59.3%
Q2 25
26.4%
59.5%
Q1 25
25.7%
Q4 24
24.6%
54.8%
Q3 24
24.0%
56.7%
Q2 24
25.2%
55.0%
Operating Margin
CBT
CBT
ENOV
ENOV
Q1 26
Q4 25
15.2%
-101.7%
Q3 25
15.2%
-3.0%
Q2 25
18.1%
-8.4%
Q1 25
17.3%
Q4 24
16.2%
-118.5%
Q3 24
15.0%
-6.3%
Q2 24
16.9%
-8.4%
Net Margin
CBT
CBT
ENOV
ENOV
Q1 26
-1.4%
Q4 25
8.6%
-104.1%
Q3 25
4.8%
-6.5%
Q2 25
10.9%
-10.0%
Q1 25
10.0%
Q4 24
9.7%
-125.4%
Q3 24
13.7%
-6.2%
Q2 24
10.7%
-3.5%
EPS (diluted)
CBT
CBT
ENOV
ENOV
Q1 26
$-0.15
Q4 25
$1.37
$-9.99
Q3 25
$0.80
$-0.64
Q2 25
$1.86
$-0.98
Q1 25
$1.69
Q4 24
$1.67
$-12.69
Q3 24
$2.41
$-0.58
Q2 24
$1.94
$-0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBT
CBT
ENOV
ENOV
Cash + ST InvestmentsLiquidity on hand
$230.0M
$33.1M
Total DebtLower is stronger
$1.3B
Stockholders' EquityBook value
$1.6B
$1.5B
Total Assets
$3.8B
$3.8B
Debt / EquityLower = less leverage
0.90×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBT
CBT
ENOV
ENOV
Q1 26
$33.1M
Q4 25
$230.0M
$33.6M
Q3 25
$258.0M
$44.1M
Q2 25
$239.0M
$38.5M
Q1 25
$213.0M
Q4 24
$183.0M
$48.2M
Q3 24
$223.0M
$35.4M
Q2 24
$197.0M
$35.0M
Total Debt
CBT
CBT
ENOV
ENOV
Q1 26
$1.3B
Q4 25
$1.4B
Q3 25
$1.1B
$1.4B
Q2 25
$1.4B
Q1 25
Q4 24
$1.3B
Q3 24
$1.1B
$1.3B
Q2 24
$1.3B
Stockholders' Equity
CBT
CBT
ENOV
ENOV
Q1 26
$1.5B
Q4 25
$1.6B
$2.0B
Q3 25
$1.6B
$2.6B
Q2 25
$1.5B
$2.6B
Q1 25
$1.4B
Q4 24
$1.4B
$2.6B
Q3 24
$1.4B
$3.3B
Q2 24
$1.3B
$3.3B
Total Assets
CBT
CBT
ENOV
ENOV
Q1 26
$3.8B
Q4 25
$3.8B
$4.4B
Q3 25
$3.8B
$5.0B
Q2 25
$3.8B
$4.9B
Q1 25
$3.8B
Q4 24
$3.6B
$4.7B
Q3 24
$3.7B
$5.6B
Q2 24
$3.6B
$5.4B
Debt / Equity
CBT
CBT
ENOV
ENOV
Q1 26
0.90×
Q4 25
0.67×
Q3 25
0.70×
0.54×
Q2 25
0.53×
Q1 25
Q4 24
0.52×
Q3 24
0.75×
0.40×
Q2 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBT
CBT
ENOV
ENOV
Operating Cash FlowLast quarter
$126.0M
Free Cash FlowOCF − Capex
$57.0M
FCF MarginFCF / Revenue
6.7%
Capex IntensityCapex / Revenue
8.1%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$401.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBT
CBT
ENOV
ENOV
Q1 26
Q4 25
$126.0M
$82.6M
Q3 25
$219.0M
$47.8M
Q2 25
$249.0M
$-1.6M
Q1 25
$73.0M
Q4 24
$124.0M
$88.3M
Q3 24
$204.0M
$53.6M
Q2 24
$207.0M
$7.8M
Free Cash Flow
CBT
CBT
ENOV
ENOV
Q1 26
Q4 25
$57.0M
$29.1M
Q3 25
$155.0M
$3.4M
Q2 25
$188.0M
$-44.9M
Q1 25
$1.0M
Q4 24
$47.0M
$35.1M
Q3 24
$112.0M
$2.4M
Q2 24
$155.0M
$-31.6M
FCF Margin
CBT
CBT
ENOV
ENOV
Q1 26
Q4 25
6.7%
5.3%
Q3 25
17.2%
0.6%
Q2 25
20.4%
-8.0%
Q1 25
0.1%
Q4 24
4.9%
6.3%
Q3 24
11.2%
0.5%
Q2 24
15.3%
-6.0%
Capex Intensity
CBT
CBT
ENOV
ENOV
Q1 26
Q4 25
8.1%
9.7%
Q3 25
7.1%
7.9%
Q2 25
6.6%
7.7%
Q1 25
7.7%
Q4 24
8.1%
9.5%
Q3 24
9.2%
10.1%
Q2 24
5.1%
7.5%
Cash Conversion
CBT
CBT
ENOV
ENOV
Q1 26
Q4 25
1.73×
Q3 25
5.09×
Q2 25
2.47×
Q1 25
0.78×
Q4 24
1.33×
Q3 24
1.49×
Q2 24
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBT
CBT

Reinforcement Materials$520.0M61%
Performance Chemicals$300.0M35%
Shipping And Handling$25.0M3%
Other Products And Services$4.0M0%

ENOV
ENOV

Segment breakdown not available.

Related Comparisons